EGF and non-small cell lung carcinoma: Our data suggested that the PR-PPD is the minimum PR domain required to inhibit NSCLC cell proliferation, and BR2 containing PR-PPD peptides effectively suppressed EGF-induced NSCLC cell, with little to no effect on noncancerous cells.